H.C. Wainwright analyst Patrick Trucchio assumed coverage of Assembly Biosciences (ASMB) with a Buy rating and $50 price target The firm sees potential for the company’s clinical-stage antiviral pipeline to deliver “significant value” in collaboration with Gilead Sciences (GILD).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- Assembly Biosciences Completes $175 Million Equity Financing
- Assembly Biosciences Announces Positive Phase 1b Results
- Assembly Biosciences announces pricing of $175M in equity financings
- Assembly Biosciences reports interim results from phase 1b study of ABI-5366
- Assembly Biosciences Reports Q2 2025 Progress and Financials